Institutional Ownership
Esperion Therapeutics Inc Ne
CUSIP 29664W105COMESPRQ1 2026
13D / 13G Filings
73
Schedule 13D/13G on record
Beneficial Filers
22
Distinct reporting persons
Largest Stake
15.9%
Max % of class reported
Institutional Holders
201
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
73 filings · latest Nov 14, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Nov 14, 2025 | Two Seas Capital LP | 13G/A | 4.7% | — | SEC |
| 2 | Nov 12, 2025 | Wasatch Advisors LP | 13G/A | 3.5% | 7.06M | SEC |
| 3 | Aug 13, 2025 | Two Seas Capital LP | 13G | 5.0% | — | SEC |
| 4 | Apr 7, 2025 | Wasatch Advisors LP | 13G/A | 5.5% | 10.93M | SEC |
| 5 | Mar 10, 2025 | Bb Biotech AG | 13G/A | 4.9% | 9.69M | SEC |
| 6 | Feb 14, 2025 | Bb Biotech AG | 13G/A | 5.0% | 9.94M | SEC |
| 7 | Nov 14, 2024 | Two Seas Capital LP | 13G/A | 3.3% | 6.58M | SEC |
| 8 | Nov 12, 2024 | Vanguard Group Inc | 13G/A | 6.6% | 13.04M | SEC |
| 9 | Nov 8, 2024 | Blackrock, Inc. | 13G | 7.3% | 14.27M | SEC |
| 10 | Nov 4, 2024 | Vanguard Group Inc | 13G/A | 6.6% | 13.04M | SEC |
63 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Esperion Therapeutics Inc Ne.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Blackrock, Inc. | 17.85M | $48.92M |
| 2 | Wasatch Advisors LP | 15.77M | $43.21M |
| 3 | Two Seas Capital LP | 11.39M | $31.22M |
| 4 | Orbimed Advisors LLC | 10.57M | $28.96M |
| 5 | Two Sigma Investments, LP | 9.46M | $25.92M |
| 6 | Marshall Wace, LLP | 7.08M | $19.39M |
| 7 | State Street Corp | 7.06M | $19.33M |
| 8 | D. E. Shaw & Co., Inc. | 6.54M | $17.92M |
| 9 | Geode Capital Management, LLC | 5.96M | $16.32M |
| 10 | Aigh Capital Management LLC | 4.40M | $12.06M |